Contents

Search

pegvisomant (Somavert)

Tradename: Somavert (FDA approved 2003) Indications: - acromegaly Dosage: daily subcutaneous injections Mechanism of action: - growth hormone receptor antagonist - normalizes growth IGF-1 levels in 90% of patients with acromegaly - no effect on growth hormone secreting tumors

General

endocrine agent

References

  1. Prescriber's Letter 11(2):suppl 2004
  2. Medical Knowledge Self Assessment Program (MKSAP) 15, American College of Physicians, Philadelphia 2009